buparlisib and Primary-Myelofibrosis

buparlisib has been researched along with Primary-Myelofibrosis* in 1 studies

Trials

1 trial(s) available for buparlisib and Primary-Myelofibrosis

Article	Year
Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica, 2019, Volume: 104, Issue:12 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Nitriles; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Tissue Distribution	2019

Article

Year

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.

Haematologica, 2019, Volume: 104, Issue:12

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Nitriles; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Tissue Distribution

2019